Compare Nano Dimension Ltd - ADR (NNDM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Repligen Corporation Common Stock — how do they compare? Nano Dimension Ltd - ADR trades at $1.39 (market cap $299.04M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 37.8× Nano Dimension Ltd - ADR's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and Repligen Corporation Common Stock for 0 Days on average.
| NNDM | RGEN | |
|---|---|---|
Market Cap | $299.04M | $11.31B |
Volume | 1,243,041 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $2.14 | $194.57 |
52-Week Low | $1.21 | $102.87 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | -$105.81M | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.45, down 3.97% with a bearish technical signal. The company reported Q2 2026 revenue of $121M but sustained a net loss of -$163M. Recent strategic moves include appointing a new board member and cost-saving initiatives expected to reduce cash burn by $25M annually. The stock shows oversold conditions with RSI at 12.66, while moving averages indicate bearish pressure.
Despite cost-cutting efforts, NNDM faces significant fundamental challenges with negative profitability margins and cash flow concerns. The company's high cash position provides some buffer, but persistent losses and leadership transitions create uncertainty. Investors should monitor execution of turnaround strategies and path to profitability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
